Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Oculis (OCS) stock jumps as the FDA grants Breakthrough Therapy designation for its eye disease drug Privosegtor targeted at ...

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Vessel density in the deep capillary plexus reflects disease activity and structural involvement in thyroid eye disease.

Investing.com -- Oculis Holding AG (NASDAQ:OCS) stock surged 9% on Tuesday after the FDA granted breakthrough therapy designation to its neuroprotective candidate Privosegtor for the treatment of ...

Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for demyelinating ...

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA ...